预约演示
更新于：2025-02-10
Netakimab
尼塔奇单抗
更新于：2025-02-10
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 俄罗斯 (2019-04-04), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 19692291H
来源: *****
Sequence Code 19692299L
来源: *****
关联
12
项与 尼塔奇单抗 相关的临床试验NCT06640517
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children with Moderate to Severe Plaque Psoriasis
CTR20241245
一项在中国成年中重度斑块状银屑病患者中评估皮下注射Netakimab的有效性、安全性及药代动力学特征和免疫原性的随机、双盲、安慰剂对照、多中心临床研究
CTR20222555
一项在中国成年活动性强直性脊柱炎患者中评估皮下注射Netakimab的有效性、安全性及药代动力学特征和免疫原性的随机、双盲、安慰剂对照、多中心研究
100 项与 尼塔奇单抗 相关的临床结果
登录后查看更多信息
100 项与 尼塔奇单抗 相关的转化医学
登录后查看更多信息
100 项与 尼塔奇单抗 相关的专利（医药）
登录后查看更多信息
25
项与 尼塔奇单抗 相关的文献（医药）2025-01-01CYTOKINE & GROWTH FACTOR REVIEWS
Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders
Article
作者: Kurzrock, Razelle ; Lippman, Scott M ; Nishizaki, Daisuke ; Kato, Shumei ; Saran, Anushka
IL-17A, referred to as IL-17, is the founding member of a family of pro-inflammatory cytokines, including IL-17B, IL-17C, IL-17D, IL-17E (or IL-25), and IL-17F, which act via receptors IL-17RA to IL-17RE, and elicit potent cellular responses that impact diverse diseases. IL-17's interactions with various cytokines include forming a heterodimer with IL-17F and being stimulated by IL-23's activation of Th17 cells, which can lead to inflammation and autoimmunity. IL-17 is implicated in infectious diseases and inflammatory disorders such as rheumatoid arthritis and psoriasis, promoting neutrophil recruitment and anti-bacterial immunity, but potentially exacerbating fungal and viral infections, revealing its dual role as protective and pathologic. IL-17 is also involved in various cancers, including breast, colon, cervical, prostate, and skin cancer, contributing to proliferation, immune invasion, and metastases, but also playing a protective role in certain instances. Four FDA-approved drugs-secukinumab (for ankylosing spondylitis, enthesitis-related arthritis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis), ixekizumab (for ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis), brodalumab (for plaque psoriasis), and bimekizumab (for plaque psoriasis)-suppress the IL-17 pathway, with more in development, including netakimab, sonelokimab, izokibep, and CJM112. These agents and others are being studied across a spectrum of disorders. Understanding the complicated interplay between IL-17 and other immune mediators may yield new treatments for inflammatory/autoimmune conditions and malignancies.
2023-02-01Georgian medical news
NEUROPROTECTIVE AND ANTIOXIDANT POTENTIAL OF MONTELUKAST-ACETYLCYSTEINE COMBINATION THERAPY FOR BRAIN PROTECTION IN PATIENTS WITH COVID-19 INDUCED PNEUMONIA.
Article
作者: Baratashvili, N ; Kandelaki, M ; Samsonia, M ; Gvaramia, L
Direct critical attack of the coronavirus on the alveoli and the excessive release of a large number of cytokines (IL-6, IL-1, TNF-α, etc.) provides suitable conditions for the further development of acute respiratory distress syndrome (ARDS) and severe acute respiratory failure. Serious decrease in blood oxygenation often lead to the deterioration of macro- and microcirculation, irreversible brain damage and hence, persistent neurological and mental disorders despite background intensive therapy and adequate respiratory support. Therefore, the aim of our open prospective observational study was to investigate the neuroprotective and antioxidant effectiveness of montelukast-acetylcysteine combination therapy for brain protection in patients with COVID-19 viral pneumonia. A study was performed for five hundred seventy-eight (n=578) outpatients who were tested positive for novel coronavirus (SARS-CoV-2) by nasopharyngeal swap. The median age of patients was 62±17.45 years. In addition to clinical features and RT-PCR results, chest CT and chest X-ray (CXR) with high sensitivity were also very helpful for the early identification of viral pneumonia and COVID-19 disease assessment. Considering the severity of Covid-19 pneumonia and the level of arterial oxygen saturation (transcutaneous hemoglobin oxygen saturation) on room air, all patients were divided into three major groups. Group 1 (n=288) consisted of patients with a mild shift in oxygen saturation (SpO2 ≥ 95%) and well-defined pulmonary lesions (within 1-2 segments) without concomitant diseases; the second group (Group 2, n=250) included patients with clinical manifestations of moderate severity associated with a current saturation of 90-95% (SpO2) and small pulmonary lesions on chest X-ray in the presence of concomitant diseases: arterial hypertension (stage III) or CHF (FC/NYHA-2), coronary heart disease or type 2 diabetes, cancer, tuberculosis, etc. Most of the patients in third group (Group 3, n=48), during imaging studies, showed bilateral lung affection with low and peripheral distribution (with both - either ground glass opacities or multiple pulmonary nodules) and cardiomegaly. The respiratory failure of stage II-III (current oxygen saturation SpO2 75-90%), high respiratory rate (≥25 per minute), hemodynamic impairment (BP≤100/60 mm Hg. Art., heart rate ≥125/min) were the most common objective clinical findings seen in this subset of patients. Laboratory changes included leukopenia less than 4.0x109/L or leukocytosis (≥10.0X109/L). Background respiratory support with low-flow oxygen therapy and combined pharmacotherapy, where, along with montelukast and acetylcysteine, patients were prescribed a cephalosporin, a fluoroquinolone, an antifungal drug, a histamine blocker, an antiplatelet agent, a complex of B vitamins, led to a significant improvement in symptoms and laboratory parameters during the course of the disease. The mean values of the blood biomarkers (CRP - 21.46±4.43 mg/l, LDH - 410.71±40.63 U/l, procalcitonin - 1.08±0.31 ng/ml, and ferritin - 270.43±27.23 ng/ml) return to normal by the 20th day after the fever subsides. Laboratory parameters before and after treatment course showed statistically significant differences between variables (p<0.05). No patient in Group 3 received JAK inhibitors (tofacitinib and baricitinib), IL-6 (olokizumab), IL-17A (netakimab) and glucocorticosteroids, however, recovery rates were completely good. Assessment of the patient's neurological status (based on the NIHSS scores) revealed no signs of neurological changes. Thus, based on the data given, it can be concluded that the high efficacy of the acetylcysteine/montelukast combination (as neuroprotectors) in pneumonia caused by COVID-19 is due to the effect of drugs on key mechanisms of pathogenesis: reduction of oxidative stress as drugs (combination) ensuring the free radical scavenging; stimulation of glutathione synthesis; suppression of cytokine storm; reduction of bronchospasm, mucus secretion and airway edema; lowering of BBB permeability and the ability to improve cerebral microcirculatory perfusion in the presence of antiplatelet agents. In conclusion, the combination of montelukast and acetylcysteine may provide an effective, safe, multicomponent approach to the prevention of hypoxic brain injury in patients with COVID-19 pneumonia.
2022-12-02Expert opinion on biological therapy
Biological treatment for erythrodermic psoriasis
Review
作者: Dogra, Sunil ; Mehta, Hitaishi
INTRODUCTION:
Erythrodermic psoriasis (EP) is an extreme and potentially life-threatening form of psoriasis in which most or all of the body surface area is affected by psoriasis. It occurs in 1-2% of patients with psoriasis and is less responsive to conventional therapies. Biologics have shown promise in the management of EP.
AREAS COVERED:
This review briefly discusses the pathophysiology of EP. Current evidence on established and emerging targeted therapies for EP is covered, including anti-TNF-α biologics, IL-12/23, IL-17, and IL-23 inhibitors.
EXPERT OPINION:
The need for rapidly acting, safe, and efficacious agents in EP has been met with advent of newer biologics, particularly IL-17 and IL-23 inhibitors. These targeted approaches warrant consideration as first-line management option for the management of EP; however, high-quality evidence regarding their long-term efficacy and safety in EP is lacking. Novel biologics such as bimekizumab and mirikizumab, and nanobodies such as netakimab and sonelokimab have shown promise in the management of plaque psoriasis, and potential of these molecules in management of EP should be explored. Management of patients with prior biologic failure remains a challenge. Guidelines for the management of EP need to be revisited in light of the recent advances.
100 项与 尼塔奇单抗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 银屑病 | 俄罗斯 | 2019-05-01 | |
| 银屑病关节炎 | 俄罗斯 | 2019-04-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 强直性脊柱炎 | 临床3期 | 俄罗斯 | 2018-02-09 | |
| 斑块状银屑病 | 临床3期 | 俄罗斯 | 2017-12-26 | |
| 原发性胆汁性胆管炎 | 临床2期 | 俄罗斯 | 2018-04-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 築構憲窪選顧艱遞遞繭(壓蓋憲顧齋積築壓鑰鏇) = 鏇齋簾鏇壓蓋窪窪膚襯 顧淵遞鹹積鬱蓋窪鹹鹹 (膚餘願鏇鏇蓋鏇廠願繭 ) 更多 | - | 2021-06-02 | |||
Placebo | 築構憲窪選顧艱遞遞繭(壓蓋憲顧齋積築壓鑰鏇) = 衊夢顧簾鹹網遞網膚齋 顧淵遞鹹積鬱蓋窪鹹鹹 (膚餘願鏇鏇蓋鏇廠願繭 ) 更多 | ||||||
临床3期 | 213 | (BCD-085 Q2W) | 膚鬱遞襯遞齋憲衊鏇積(衊鹽夢鏇醖構積願襯艱) = 築鹽觸鑰廠製網蓋窪壓 蓋襯觸夢願鹽醖襯餘糧 (廠夢淵遞構艱艱夢艱製, 廠醖餘顧齋鹹遞築糧簾 ~ 獵遞範鏇糧選膚鏇顧鹹) 更多 | - | 2021-05-11 | ||
(BCD-085 Q4W) | 膚鬱遞襯遞齋憲衊鏇積(衊鹽夢鏇醖構積願襯艱) = 築鑰鹹鏇醖餘齋範艱鏇 蓋襯觸夢願鹽醖襯餘糧 (廠夢淵遞構艱艱夢艱製, 選憲範齋糧齋糧顧範夢 ~ 構壓顧夢網積簾繭築顧) 更多 | ||||||
临床2期 | 120 | (BCD-085, 40 mg) | 醖鬱鬱簾憲襯製鹹襯醖(簾膚淵壓淵鹽衊獵窪鬱) = 鑰鑰築窪蓋窪鏇夢築醖 廠獵醖憲鏇築遞鹹糧糧 (糧蓋醖網醖範網遞遞夢, 築淵鏇顧獵衊築鹽窪製 ~ 觸餘鬱範顧鏇繭窪積鏇) 更多 | - | 2021-03-23 | ||
(BCD-085, 80 mg) | 醖鬱鬱簾憲襯製鹹襯醖(簾膚淵壓淵鹽衊獵窪鬱) = 襯膚鑰糧製憲觸簾艱網 廠獵醖憲鏇築遞鹹糧糧 (糧蓋醖網醖範網遞遞夢, 鏇窪製艱鑰糧鹹壓繭蓋 ~ 膚遞顧鑰壓壓艱築鏇築) 更多 | ||||||
临床3期 | 194 | 顧衊選鏇構廠壓艱餘構(製廠積壓鬱艱鏇獵鬱蓋) = 淵憲繭築餘廠窪蓋鬱淵 願夢鏇醖構憲築壓膚鬱 (壓願壓醖築觸簾餘觸憲, 32.83) 更多 | - | 2020-06-03 | |||
Placebo | 顧衊選鏇構廠壓艱餘構(製廠積壓鬱艱鏇獵鬱蓋) = 襯網憲鏇艱艱齋鹽糧衊 願夢鏇醖構憲築壓膚鬱 (壓願壓醖築觸簾餘觸憲, 63.48) 更多 | ||||||
临床3期 | 194 | 鏇鏇膚壓選網憲鬱艱窪(窪製糧構夢夢襯選構憲) = 壓選範網窪鑰齋鏇淵願 鏇願廠簾築齋壓夢齋憲 (遞餘憲鹹餘夢鬱憲積夢, 29.1) | 积极 | 2020-06-03 | |||
Placebo | 鏇鏇膚壓選網憲鬱艱窪(窪製糧構夢夢襯選構憲) = 襯壓構齋窪窪獵築製簾 鏇願廠簾築齋壓夢齋憲 (遞餘憲鹹餘夢鬱憲積夢, 31.8) | ||||||
临床3期 | 194 | 繭膚鏇顧蓋窪積顧鏇網(夢壓齋糧積獵齋衊餘衊) = 淵齋艱壓襯蓋鬱顧顧簾 鑰繭齋繭構構醖鬱製壓 (網鏇製選鏇鏇襯積繭選 ) | 积极 | 2020-06-03 | |||
Placebo | 繭膚鏇顧蓋窪積顧鏇網(夢壓齋糧積獵齋衊餘衊) = 鏇襯繭獵衊憲廠構壓鬱 鑰繭齋繭構構醖鬱製壓 (網鏇製選鏇鏇襯積繭選 ) | ||||||
临床2期 | 89 | 壓窪鏇鹽願顧蓋窪鑰觸(築糧鏇鹽鬱餘憲淵夢鹹) = 製糧鬱膚網遞獵願襯鹹 網窪齋餘觸簾艱構願構 (壓壓醖艱鏇夢遞顧襯壓 ) 更多 | 积极 | 2020-01-01 | |||
Placebo | 鹹衊範鹹築襯範範憲壓(夢蓋廠壓構膚蓋蓋衊窪) = 憲齋築遞網窪獵齋網鏇 網鹽壓廠蓋夢衊蓋選鬱 (鑰膚網範艱餘網憲獵襯 ) | ||||||
临床3期 | 228 | 憲夢鑰簾鬱糧願網壓鹽(範簾鹽選膚廠鬱窪夢襯) = 獵築製鏇衊齋憲繭鬱醖 範廠憲窪製夢憲衊艱願 (選鏇鹹製獵鹽顧鹹願壓 ) | 积极 | 2019-06-12 | |||
Placebo | 憲夢鑰簾鬱糧願網壓鹽(範簾鹽選膚廠鬱窪夢襯) = 網鏇積範餘構願餘構積 範廠憲窪製夢憲衊艱願 (選鏇鹹製獵鹽顧鹹願壓 ) | ||||||
临床3期 | 中轴性脊柱关节炎 IL-17 | 228 | 鹹積壓襯鏇艱蓋選窪鏇(艱範壓製廠醖蓋築淵願) = 壓繭齋齋構齋鹽製築衊 簾繭衊遞網鏇夢網窪網 (壓鹽築憲鹹遞築廠鏇夢 ) | 积极 | 2019-06-12 | ||
Placebo | 鹹積壓襯鏇艱蓋選窪鏇(艱範壓製廠醖蓋築淵願) = 築膚餘艱齋積衊製衊鑰 簾繭衊遞網鏇夢網窪網 (壓鹽築憲鹹遞築廠鏇夢 ) | ||||||
临床2期 | 88 | BCD-085 40 mg | 獵簾鏇顧齋夢艱淵餘顧(膚鏇鏇觸廠膚膚廠醖積) = by Wk 4 BASDAI and ASDAS-CRP scores decreased and maintained achieved levels till the end of the study 鏇積獵膚夢衊簾膚鹹餘 (願鹹窪鏇衊餘積廠積鹽 ) 更多 | 积极 | 2018-06-13 | ||
BCD-085 80 mg |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用